Skip to main content
. Author manuscript; available in PMC: 2022 May 15.
Published in final edited form as: Brain Res. 2021 Feb 15;1759:147372. doi: 10.1016/j.brainres.2021.147372

Figure 3. Reduced pT73-Rab10 and pS106-Rab12 levels in Long-Evans rats treated with the LRRK2 kinase inhibitor PF-475.

Figure 3.

a. Representative immunoblots for detecting Lrrk2 and Rab proteins in forebrain lysates from Lrrk2 knockout (KO) and Long Evans (LE) rats treated with a high dose of PF-475 (30 mg·kg−1) or vehicle control. Tissue was collected two hours post-dosing. Quantification of b. total Lrrk2 protein levels normalized to HSC70 and c. pS935-Lrrk2 levels normalized to total Lrrk2 protein. Quantification of pT73-Rab10 levels normalized to d. HSC70 and e. total Rab10 protein. Quantification of pS106-Rab12 levels normalized to f. HSC70 and g. total Rab12. Data are graphed as average measures from triplicate western blots for biological replicates (N=3 rats per group). All values are presented as fold changes to the vehicle treated group. Bar graphs show group means ± SEM. Significance between treated and untreated (vehicle) controls was determined using two-tailed unpaired t-tests. Data in panels d and e were log transformed prior to t-tests to better approximate normal group distributions. *p< 0.05, **p< 0.01, ***p< 0.001, ns is not significant.